Binh Nguyen

Do you see hair in this injectable solution? Injectable solutions are critical in modern medicine, delivering life-saving drugs directly into the body. Despite advances in pharmaceutical technology, the presence of particulate matter in these solutions remains a significant concern. Particulate contamination can compromise patient safety, affect drug efficacy, and lead to serious health complications. This issue has persisted for decades, prompting ongoing research and regulatory efforts to...

It depends on whom you work for...Two important highlights: 1. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize - On April 01, 2026, FDA clarifies policies for compounders. The FDA stated that a compounded drug product is considered essentially a copy of a commercially available drug product if · The compounded drug product contains the same APIs as two or more commercially available drug products in the same,...

Receiving a warning letter (WL) from the Food and Drug Administration (FDA) can be a critical moment for any company in the pharmaceutical, food, or medical device industries. These letters highlight serious regulatory violations and demand prompt corrective actions. Successfully addressing these concerns is essential not only to avoid legal consequences but also to maintain trust with consumers and regulators. This post explores practical strategies to navigate remediation efforts...